Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Boehringer Ingelheim

Evaluate

Thumbnail
June 05, 2023

Akero suggests the limits of GLP-1s in Nash

Thumbnail
May 25, 2023

Lilly steps up its oral obesity push  

Article image
Vantage logo
May 10, 2023

Boehringer and Zealand take a baby step in obesity

Article image
Vantage logo
May 05, 2023

Spotlight – Travere trips up but others are following in rare kidney disease

Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.

Article image
Vantage logo
May 02, 2023

Pliant’s latest lung disease data fail to convince

Article image
Vantage logo
April 13, 2023

Zealand seeks deals in obesity and beyond

With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.

Article image
Vantage logo
April 04, 2023

In with a Ror1, out with a whimper

Article image
Vantage logo
April 03, 2023

Spotlight – following Humira in hidradenitis suppurativa

Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.

Article image
Vantage logo
March 29, 2023

Boehringer signals intent in obesity

Obesity is biopharma’s hottest ticket, and Boehringer Ingelheim wants a seat at the show.

Article image
Vantage logo
March 23, 2023

Merkel cell provides Incyte’s laggard a way in

Article image
Vantage logo
February 24, 2023

Spotlight – Cystic fibrosis developers take a deep breath

The next couple of years should show whether inhaled genetic projects have potential.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up